NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS IN WHOLE OR IN PART FOR LEGAL RESTRICTIONS.
THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES IN RLS GLOBAL AB.
SEE THE "IMPORTANT INFORMATION" SECTION BELOW.
The board of administrators of RLS International AB (publ) (the "Firm" or "RLS International") has as we speak, pursuant to the authorization granted by the annual normal assembly on 19 Might 2022, resolved on a brand new share problem of roughly SEK 29.4 million with preferential rights for current shareholders (the "Rights Challenge").
The rights problem is absolutely assured by subscription commitments and assure commitments.
Background and cause for the Rights Challenge RLS International is a Swedish medical know-how firm that develops, manufactures, and sells merchandise primarily based on the Firm's hypochlorite platform for the therapy of illnesses within the space of difficult-to-heal wounds in wound care each in sufferers and in animals.
The corporate offers merchandise with the purpose of making as clear a wound as doable with the purpose of supporting efficient wound therapeutic.
RLS International has, by its personal analysis, developed the product ChloraSolv ® .
ChloraSolv ® shortly and successfully loosens micro organism within the biofilm, in vitro, whereas being non-irritating to wholesome tissue.
ChloraSolv ® is used with good impact on leg ulcers and diabetic foot ulcers with the purpose of eradicating devitalized tissue and thus selling pure wound therapeutic.
ChloraSolv ® consists of a two-component system, the place one of many elements is a gel and the opposite is a hypochlorite resolution.
ChloraSolv ® is a therapy that's utilized in all segments of healthcare, specialist care, main care, and residential well being care.
Sufferers with difficult-to-heal wounds bear giant healthcare prices, and there are various constructive health-economic advantages in that sufferers might be handled with ChloraSolv ® in all segments.
RLS International and ConvaTec, a world firm in superior wound care, have entered into an settlement for ConvaTec to take international duty for launching ChloraSolv ® .
The collaboration consists of rights to commercialize ChloraSolv ® in Europe and future rights to commercialize the product within the US and the remainder of the world after regulatory approvals.
The corporate is concentrated on the continued launch of ChloraSolv ® by strategic gross sales companions in Europe, the Center East and inside Animal Well being in Scandinavia, and can be making ready the launch in expanded indications for the product.
With a purpose to drive and speed up this launch, the Firm launches highly effective industrial efforts and market investments and likewise ensures the provision chain to satisfy a enormously elevated demand and volumes.
As well as, working capital is required for the Firm's normal operations by the continued launch part.
Abstract of the Rights Challenge Full phrases and directions for the Rights Challenge in addition to different details about the Firm will likely be out there within the EU development prospectus, which is predicted to be printed round October 25, 2022.
The timetable is preliminary and should change, amongst different issues primarily based on the processing time for the present prospectus.
Underwriting obligations and assure commitments The rights problem is absolutely assured by subscription- and assure commitments akin to a complete of SEK 29.4 million.
The subscription commitments quantity to roughly SEK 17.0 million, akin to roughly 57.75 p.c of the Rights problem, and the assure commitments quantity to roughly SEK 12.4 million, akin to roughly 42.25 p.c of the Rights problem.
Assure commitments consists of prime assure commitments and backside assure commitments.
High assure commitments quantity to roughly SEK 6,3 million, akin to roughly 21,4 p.c of the Rights Challenge.
Backside assure commitments quantity to roughly SEK 6,1 million, akin to roughly 20,9 p.c of the Rights Challenge.
Subscription and assure commitments from senior executives and board members quantity to a complete of SEK 6.5 million.
The subscription commitments and ensures commitments have been agreed upon in writing.
No compensation is paid for the subscription commitments.
No compensation is paid for prime ensures supplied, for different backside ensures a compensation of fourteen (14) p.c of the assured quantity is paid.
The commitments and ensures are usually not secured by financial institution assure, escrow funds, pledging or comparable preparations.
The subscription- and assure commitments has been coordinated by the Firm's monetary advisor Erik Penser Financial institution and all guarantors might be reached by way of the next handle: Apelbergsgatan 27, 111 37 Stockholm Preliminary schedule for the Rights Challenge October 24, 2022 Final buying and selling day within the share with the best to take part within the Rights Challenge October 25, 2022 First buying and selling day within the share with out the best to take part within the Rights Challenge October 26, 2022 Document date for participation within the Rights Challenge October 25, 2022 Estimated date for publication of prospectus October 28 - November 8, 2022 Buying and selling in subscription rights October 28 -November 11, 2022 Subscription interval November 16, 2022 Estimated date for publication of the end result of the Rights Challenge Change in share capital and variety of shares and dilution Via the Rights Challenge, the share capital within the Firm will increase by a most of SEK 1,108,341.98446, from SEK 7,916,732.4151 to SEK 9,025,074.3996, by the issuance of a most of 9,809,170 shares.
The variety of shares thus will increase from 70,065,535 to a most of 79,874,705 shares.
For current shareholders who don't take part within the Rights Challenge, this implies, within the case of full subscription, a dilution impact of 12.3 p.c of capital and votes within the Firm.
Advisor RLS International has engaged Erik Penser Financial institution AB and Baker & McKenzie Advokatbyrå KB as monetary and authorized advisors respectively in reference to the Rights Challenge.
For additional info contact: Björn Larsson, CEO, RLS International E-mail: bjorn.larsson@rlsglobal.se Telephone: +46 766 20 17 25 Buying and selling venue and Licensed Adviser: The share has been listed on the Nasdaq First North Development Market since Might 17, 2017 and is traded below the quick title RLS.
Previous to that, the Firm was listed on Aktietorget.
Licensed Adviser is Redeye Aktiebolag.
Vital info The data on this press launch neither incorporates nor constitutes a proposal to accumulate, subscribe or in any other case commerce in shares, warrants or different securities in RLS International.
No motion has been taken and no motion will likely be taken to allow a proposal to the general public in any jurisdictions aside from Sweden.
The invitation to individuals to subscribe for shares in RLS International will solely happen by the prospectus that RLS International expects to have the ability to publish round October 25, 2022.
The data contained on this press launch is probably not disclosed, printed or distributed, instantly or not directly, inside or to america, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, Russia, Belarus or another jurisdiction the place such motion can be unlawful, topic to authorized restrictions or require measures aside from those who comply with from Swedish legislation.
Actions opposite to this instruction might represent a violation of relevant securities laws.
No shares or different securities of RLS International have been registered, and no shares or different securities will likely be registered, below america Securities Act of 1933 infrequently ("Securities Act") or the securities legal guidelines of any state or different jurisdiction of america and is probably not provided, offered or in any other case transferred, instantly or not directly, in or to america, besides pursuant to an relevant exemption from, or in a transaction not topic to, the registration necessities of the Securities Act and pursuant to the securities legal guidelines of the related state or different jurisdiction in america.
This communication is distributed to and directed solely to individuals in the UK who're (i) skilled traders falling throughout the scope of Article 19(5) of the U.Okay. infrequently in power; Monetary Providers and Markets Act 2000 (Monetary Promotion) Order 2005 ("the Order") or (ii) excessive web value topics and different individuals to whom this discover might lawfully be addressed, who're topic to Article 49(2)(a)-(d) ) within the Order (all such individuals are collectively known as "Related Individuals").
Individuals who are usually not Related Individuals might not act on or depend on the data on this communication.
An funding or funding measure referred to on this communication is barely doable for Related Individuals and can solely be accomplished with Related Individuals.
Individuals who disseminate this communication should themselves make sure that such dissemination is permitted.
Ahead-looking statements This press launch incorporates forward-looking statements that seek advice from the Firm's intentions, assessments or expectations concerning the Firm's future outcomes, monetary place, liquidity, improvement, prospects, anticipated development, methods and alternatives in addition to the markets through which the Firm operates.
Ahead-looking statements are statements that don't relate to historic info and might be recognized by the inclusion of expressions comparable to "believes", "expects", "anticipates", "intends", "estimates", "will", "might", "assumes", "ought to" "may" and, in every case, negations thereof, or comparable expressions.
The forward-looking statements on this press launch are primarily based on varied assumptions, which in a number of circumstances are primarily based on extra assumptions.
Though the Firm believes that the assumptions mirrored in these forward-looking statements are cheap, there might be no assurance that they may happen or that they're correct.
As these assumptions are primarily based on assumptions or estimates and are topic to dangers and uncertainties, the precise end result or consequence might, for a lot of completely different causes, differ materially from what seems within the forward-looking statements.
Such dangers, uncertainties, contingencies, and different materials components might trigger precise occasions to vary materially from the expectations expressed or implied on this press launch by the forward-looking statements.
The Firm doesn't warrant that the assumptions underlying the forward-looking statements on this press launch are right and any reader of the press launch shouldn't place undue reliance on the forward-looking statements on this press launch.
The data, opinions and forward-looking statements expressed or implied herein are supplied solely as of the date of this press launch and are topic to alter.
Neither the Firm nor anybody else undertakes to revise, replace, affirm or publicly announce any revision of any forward-looking assertion to replicate occasions occurring or circumstances occurring with respect to the contents of this press launch, besides as required by legislation or Nasdaq First North Development Markets' laws for issuers.
RLS International (publ) is obliged to make the data contained herein public pursuant to the EU market abuse regulation (MAR).
The data was submitted for publication by the company of the above contact individual, 19-10-2022 19:45 CET. https://news.cision.com/rls-global-ab/r/rls-global--rls-global-resolves-on-a-fully-guaranteed-rights-issue-of-approximately-sek-29-4-million,c3651527 (c) 2022 Cision.